CN108135889A - 用于在危重监护治疗期间使用的镇静方法和肠胃外制剂 - Google Patents

用于在危重监护治疗期间使用的镇静方法和肠胃外制剂 Download PDF

Info

Publication number
CN108135889A
CN108135889A CN201680059253.3A CN201680059253A CN108135889A CN 108135889 A CN108135889 A CN 108135889A CN 201680059253 A CN201680059253 A CN 201680059253A CN 108135889 A CN108135889 A CN 108135889A
Authority
CN
China
Prior art keywords
gaboxadol
pharmaceutically acceptable
acceptable salt
administered
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680059253.3A
Other languages
English (en)
Chinese (zh)
Inventor
马修·杜林
安娜·卡赞奇彦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ovid Therapeutics Inc
Original Assignee
Ovid Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/834,027 external-priority patent/US9399034B1/en
Application filed by Ovid Therapeutics Inc filed Critical Ovid Therapeutics Inc
Priority claimed from PCT/US2016/045094 external-priority patent/WO2017027249A1/en
Publication of CN108135889A publication Critical patent/CN108135889A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Anesthesiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CN201680059253.3A 2015-08-11 2016-08-02 用于在危重监护治疗期间使用的镇静方法和肠胃外制剂 Pending CN108135889A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201562203731P 2015-08-11 2015-08-11
US201562203748P 2015-08-11 2015-08-11
US62/203,748 2015-08-11
US62/203,731 2015-08-11
US14/834,027 2015-08-24
US14/834,027 US9399034B1 (en) 2015-08-11 2015-08-24 Methods of sedation during critical care treatment
US15/185,650 2016-06-17
US15/185,650 US9717716B2 (en) 2015-08-11 2016-06-17 Methods of sedation during critical care treatment
PCT/US2016/045094 WO2017027249A1 (en) 2015-08-11 2016-08-02 Methods of sedation and parenteral formulation for use during critical care treatment

Publications (1)

Publication Number Publication Date
CN108135889A true CN108135889A (zh) 2018-06-08

Family

ID=59687449

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680059253.3A Pending CN108135889A (zh) 2015-08-11 2016-08-02 用于在危重监护治疗期间使用的镇静方法和肠胃外制剂

Country Status (12)

Country Link
US (1) US20180235942A1 (enExample)
EP (1) EP3334427A4 (enExample)
JP (1) JP6857647B2 (enExample)
KR (1) KR20180048707A (enExample)
CN (1) CN108135889A (enExample)
AU (1) AU2016304737B2 (enExample)
CA (1) CA2994952A1 (enExample)
CO (1) CO2018002534A2 (enExample)
IL (1) IL257296B2 (enExample)
MX (1) MX394213B (enExample)
PE (1) PE20181332A1 (enExample)
TW (1) TWI763632B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL256912B2 (en) 2015-07-17 2024-01-01 Ovid Therapeutics Inc Methods of treating developmental disorders with gaboxadol
WO2018031748A1 (en) 2016-08-11 2018-02-15 Ovid Therapeutics Inc. Methods and compositions for treatment of epileptic disorders
US10071083B2 (en) 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
WO2020061410A1 (en) 2018-09-20 2020-03-26 Ovid Therapeutics Inc. Use of gaboxadol for the treatment of tourette syndrome, tics and stuttering
GB2594616A (en) 2018-11-21 2021-11-03 Certego Therapeutics Inc Gaboxadol for reducing risk of suicide and rapid relief of depression
CN113423399A (zh) 2018-12-17 2021-09-21 奥维德医疗公司 加波沙朵用于治疗非24小时睡眠-觉醒障碍的用途
IL298334A (en) 2020-05-20 2023-01-01 Certego Therapeutics Inc Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders
US20220218740A1 (en) * 2020-10-25 2022-07-14 Vaporworks Nursing Anesthesia Inc. Opioid-free compositions for anesthesiological applications and related methods and systems

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005063248A1 (en) * 2003-12-22 2005-07-14 Sepracor Inc. Modafinil combination therapy for improving sleep quality

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6071933A (en) * 1999-12-03 2000-06-06 Diversified Medical Innovations, Inc. Homogeneous remifentanil-propofol blend for patient controlled anesthesia and process for its use
JP2007523165A (ja) * 2004-02-18 2007-08-16 セプレイコー インコーポレイテッド 睡眠の質を改善するためのドーパミン作動薬併用療法
US20090143335A1 (en) * 2007-10-29 2009-06-04 H. Lundbeck A/S Modified absorption formulation of gaboxadol
US9399034B1 (en) * 2015-08-11 2016-07-26 Ovid Therapeutics Inc Methods of sedation during critical care treatment

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005063248A1 (en) * 2003-12-22 2005-07-14 Sepracor Inc. Modafinil combination therapy for improving sleep quality

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PATRIK PANDHARIPANDE AND E WESLEY ELY: "Narcotic-based sedation regimens for critically ill mechanically ventilated patients", 《CRITICAL CARE》 *
VALENTIN N ET AL: "RESPIRATORY EFFECT OF THIP, A GABA-AGONISTIC ANALGESIC, DURING HALOTHANE ANAESTHESIA"", 《ACTA ANAESTHESIOLOGICA SCANDINAV》 *

Also Published As

Publication number Publication date
IL257296B2 (en) 2023-02-01
CA2994952A1 (en) 2017-02-16
PE20181332A1 (es) 2018-08-20
AU2016304737A1 (en) 2018-02-22
IL257296A (en) 2018-03-29
EP3334427A1 (en) 2018-06-20
KR20180048707A (ko) 2018-05-10
TW201717944A (zh) 2017-06-01
US20180235942A1 (en) 2018-08-23
MX2018001720A (es) 2018-09-06
JP6857647B2 (ja) 2021-04-14
TWI763632B (zh) 2022-05-11
MX394213B (es) 2025-03-24
AU2016304737B2 (en) 2021-03-11
IL257296B (en) 2022-10-01
EP3334427A4 (en) 2019-02-06
JP2018522920A (ja) 2018-08-16
CO2018002534A2 (es) 2018-05-31

Similar Documents

Publication Publication Date Title
TWI763632B (zh) 用於重症治療時之鎮靜方法及非口服調配物
US11806336B2 (en) Methods and compositions for treatment of epileptic disorders
US10111865B2 (en) Methods of sedation during critical care treatment
US20210379028A1 (en) Treatment of depressive disorders
WO2017027249A1 (en) Methods of sedation and parenteral formulation for use during critical care treatment
JP6818019B2 (ja) レファムリンの注射可能医薬組成物
CN104918619A (zh) 稳定的肠胃外dnj组合物
US20220110917A1 (en) Use of gaboxadol, ganaxolone and allopregnanolone to treat movement disorders
CN107961215B (zh) 一种左西替利嗪注射剂
WO2014059363A1 (en) Oral solution formulations of aripiprazole
HK1256349A1 (zh) 用於在危重监护治疗期间使用的镇静方法和肠胃外制剂
CN108430581A (zh) 用于利扎曲普坦的药物组合物
HK40121582A (zh) 用於治疗癫痫性紊乱的方法和组合物
HK40027257A (en) Treatment of depressive disorders

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1256349

Country of ref document: HK

RJ01 Rejection of invention patent application after publication

Application publication date: 20180608

RJ01 Rejection of invention patent application after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1256349

Country of ref document: HK